Investor Presentation

87 Investor presentation First six months of 2022 Novo Nordisk is expanding into other serious chronic diseases Serious chronic diseases are often associated with diabetes and obesity New therapeutic areas represent patient populations with high unmet medical needs Novo NordiskⓇ Estimated patients AD Patients with AD live from 2 to 20 years from dementia onset AD ~85 million Available treatments No approved disease modifying medical treatments 70% of people with diabetes die from atherosclerotic CVD Estimated patients Number of related deaths CVD 40% of people hospitalised for heart failure have diabetes CVD ~420 million -20 million annually Estimated patients NASH 80% of people with NASH live with obesity and 35% have diabetes NASH ~15-40 million¹ CKD • 40% of people with diabetes have diabetic nephropathy and 50% have obesity CKD ~200 million Diagnosis rate -20%2 -20% 1 Internal forecast comprising the USA, Europe and Japan; 2 Diagnosis rate is considered a major uncertainty to the forecast CVD: Cardiovascular disease; NASH: Non-alcoholic Steatohepatitis; CKD: Chronic kidney disease; AD: Alzheimer's Disease Sources: Alzheimer's Association report: 2020 Alzheimer's disease facts and figures, 2020 (16:391-460), Diabetes Care 2005 Jan; 28(1): 164-176; Abera SF et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015, 2017; Heart Disease and Stroke Statistics, American Heart Association, 2017; Williams CD et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy, 2011; Addressing the global burden of chronic kidney disease through clinical and translational research, 2014

View entire presentation